If I had $50,000 to deploy into ASX 200 blue chips today, I would try and focus on quality.
This means market leaders and businesses with competitive advantages and the ability to grow earnings over time.
They may not necessarily be the cheapest stocks on the board, but companies I'd feel comfortable holding through multiple market cycles.
Here's where I'd start.
Image source: Getty Images
Cochlear Ltd (ASX: COH)
Cochlear is a global leader in implantable hearing solutions, operating in a niche that requires deep expertise, regulatory approval, and long-term relationships with surgeons and hospitals.
This is not a business that can be easily disrupted. The barriers to entry are high, the product is life-changing, and switching providers is not straightforward.
While earnings can fluctuate depending on procedure volumes and currency movements, I believe the long-term growth drivers remain intact. Ageing populations and improving access to healthcare globally should support demand for decades.
For me, Cochlear represents high-quality healthcare exposure with global reach.
Goodman Group (ASX: GMG)
Goodman is one of the world's leading industrial property groups, focused on logistics facilities, warehouses, and increasingly data centre-related infrastructure.
What I like most is its development capability and capital-light model. It partners with institutional capital, earns management fees, and captures development profits, rather than simply owning static assets.
The long-term tailwinds from ecommerce, supply chain reconfiguration, and digital infrastructure demand continue to support its strategy.
Even though the property sector can be cyclical, I think Goodman's positioning in high-demand assets makes it one of the strongest ASX 200 blue chip stocks out there.
Woolworths Group Ltd (ASX: WOW)
Woolworths gives exposure to essential spending. Supermarkets tend to be resilient across economic cycles. People might cut back on discretionary items, but they still buy groceries. That gives Woolworths relatively defensive earnings characteristics.
While the company has faced operational challenges and leadership upheaval in recent periods, I think its dominant market position and scale advantages remain powerful over the long run.
As part of a $50,000 ASX 200 blue chip stock allocation, I'd want at least one defensive consumer staple in the mix and Woolworths ticks all the boxes.
Wesfarmers Ltd (ASX: WES)
Wesfarmers is more than just a retailer. With assets including Bunnings, Kmart, and other industrial and chemical operations, it combines strong retail cash flows with disciplined capital allocation.
What stands out to me is management's willingness to transform its portfolio when the time comes. That capital discipline is a big reason the company has compounded value over time.
As a core blue chip holding, I think Wesfarmers provides both resilience and growth optionality.
Sigma Healthcare Ltd (ASX: SIG)
Over the last 12 months, Sigma has transformed itself through its merger with Chemist Warehouse, creating a vertically integrated pharmacy and wholesale powerhouse.
That deal gives Sigma exposure not just to distribution margins but also to one of Australia's most recognisable retail pharmacy brands. The combined entity benefits from scale, procurement power, and strong brand recognition.
Healthcare spending is generally non-discretionary, and I see long-term demand supported by population growth and ageing demographics.
For a blue chip with exposure to both retail and healthcare, Sigma adds a different growth and income dynamic to the portfolio.
Foolish takeaway
If I were investing $50,000 into ASX 200 blue chip stocks today, I'd consider spreading it across quality businesses with different drivers.
Cochlear, Goodman, Woolworths, Wesfarmers, and Sigma Healthcare each bring something different to the table. Together, I believe they form a balanced foundation built for long-term compounding.
